MedTrace Logo

Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence

NCT02447679 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-02-07

No results posted yet for this study

Summary

This single-centered phase II clinical study is to obtain preliminary information on 1-year recurrence-free survival rate, recurrence-free survival and safety profile of thalidomide in combination with tegafur-uracil in hepatocellular carcinoma after hepatectomy and explore biomarkers(VEGF/bFGF) for thalidomide response.

Conditions

  • Adult Hepatocellular Carcinoma
  • Recurrent Hepatocellular Carcinoma
  • Adverse Reaction to Drug
  • Vascular Endothelial Growth Factor Overexpression

Interventions

DRUG

thalidomine

thalidomine (400mg/day) for 1 year to prevent HCC recurrence

DRUG

tegafur-uracil

tegafur-uracil (2 tablelet twice a day) for 1 year to prevent HCC recurrence

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    lead OTHER

Principal Investigators

  • Wei-Chen Lee · Chang Gung Memorial Hospital

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2017-01-31
Completion
2017-02-02

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02447679 on ClinicalTrials.gov